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The relationship of thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms on 5-
fluorouracil (FU) sensitivity was tested on 19 human cancer cell lines (head and neck, breast, digestive tract) in the absence and
presence of folinic acid (FA) supplementation. Thymidylate synthase polymorphisms in the 50 promoter region (double or triple
tandem repeats) and 30 untranslated region (6-bp deletion) were analysed by PCR. The C677T and A1298C MTHFR polymorphisms
were determined by melting curve analyses (LightCycler). Thymidylate synthase activity and intracellular concentration of the
reduced folate 5-10 methylenetetrahydrofolate (CH2FH4) were measured (biochemical assays). Thymidylate synthase activity was
significantly different according to 50 TS genotype, heterozygous cell lines (2R/3R) exhibiting higher TS activities than homozygous
ones (P¼0.05). However, whether in the absence or presence of FA, FU sensitivity was not statistically associated with either 50 or 30
TS polymorphism. Basal CH2FH4 cellular concentrations were lowest in C677T homozygous wild-type (wt) (C/C) cell lines. FU
sensitivity was not linked to C677T polymorphism. In contrast, there was a marked trend for a greater FU efficacy in mutated
A1298C variants (C/CþA/C) as compared to wt homozygous cell lines (A/A) (P¼0.055 and 0.085 without and with FA
supplementation, respectively). These results suggest for the first time a potential role of A1298C MTHFR polymorphism on
fluoropyrimidine sensitivity.
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5-Fluorouracil (FU) and fluoropyrimidine prodrugs remain the
drugs of choice for the treatment of colorectal (Wils et al, 2001),
breast (Fumoleau et al, 2003) and head and neck cancers (Posner
et al, 2000). The conversion of FU into fluorodeoxyuridine
monophosphate (FdUMP) leads to the inhibition of thymidylate
synthase (TS, EC 2.1.1.45, the key enzyme of de novo deoxythy-
midine 50-monophosphate synthesis, Figure 1) and subsequent
DNA synthesis arrest. The presence of FdUMP induces the
formation of an inactive ternary complex between TS, FdUMP,
and the methyl donor-reduced folate 5-10 methylenetetrahydrofo-
late (CH2FH4). Experimental studies have clearly established that
the stabilisation of the ternary complex, and thus optimal TS
inhibition, requires elevated cellular concentrations of CH2FH4
(Danenberg and Danenberg, 1978; Houghton et al, 1981; Rustum
et al, 1987; Keyomarsi and Moran, 1988; Che ´radame et al, 1997a).
Accordingly, clinical studies have demonstrated higher antitumour
efficacy when FU is associated with folinic acid (FA), a precursor
of CH2FH4 (Petrelli et al, 1987; Poon et al, 1989; Doroshow et al,
1990; Piedbois et al, 1992; Ja ¨ger et al, 1996). We previously closely
studied the role of FA supplementation and CH2FH4 intratumoral
concentration on FU efficacy in a panel of 14 human cell lines
(Che ´radame et al, 1997a). Moreover, in patients receiving
cisplatin–FU chemotherapy, we previously supplied direct evi-
dence of the role of intratumoral CH2FH4 on FU efficacy, with
significantly lower tumoral CH2FH4 concentrations in nonre-
sponding patients as compared to responding patients (Che ´ra-
dame et al, 1997b).
The intracellular CH2FH4 concentration is mainly controlled by
the methylenetetrahydrofolate reductase enzyme (MTHFR, EC
1.5.1.20), which irreversibly converts CH2FH4 into 5-methyltetra-
hydrofolate (Figure 1) (Scott and Weir, 1994). Methylenetetrahy-
drofolate reductase is located at a major metabolic crossroad,
directing the folate pool towards remethylation of homocysteine to
methionine (and subsequent DNA methylation) at the expense of
DNA synthesis (Figure 1). Methylenetetrahydrofolate reductase
gene is located on chromosome 1p, and is subject to several
polymorphisms (Rozen, 1996). Among them, the C677T (exon 4)
and A1298C (exon 7) single-nucleotide polymorphisms (SNPs) are
the two most commonly linked with altered phenotypes, both
associated with lower enzyme activity (Frosst et al, 1995; Weisberg
et al, 1998). The frequency of the mutated 677 TT genotype is
around 10–15% in Caucasians, and only a few percent in Afro-
Americans (Ueland et al, 2001). The 677C4T mutation enhances
the thermolability of the enzyme (Frosst et al, 1995). The mutated
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s677 TT genotype is associated with elevated plasma homocysteine
concentrations, as well as DNA hypomethylation that is involved in
carcinogenesis processes. The influence of C677T polymorphism
on disease risk is closely related to the nutritional folate status. In
case of folate intake deficiency, 677 TT genotype is related to
increased risk of congenital neural tube defect and to colorectal
cancer (Ueland et al, 2001). The A1298C genotype has been less
extensively studied (Van der Put et al, 1998; Weisberg et al, 1998)
and the frequency of the mutated 1298 CC genotype reported in
Japanese patients is around 3% (Urano et al, 2002). Interestingly,
Urano et al (2002) recently reported that the mutated 677 TT
genotype was associated with greater methotrexate toxicity,
whereas the mutated 1298 CC genotype was linked with better
methotrexate efficacy. Since MTHFR enzymatic deficiency may
theoretically favour thymidine synthesis via an increase of
CH2FH4, one can hypothesise that tumours exhibiting mutated
MTHFR genotypes linked to enzymatic deficiency may be more
sensitive to FU cytotoxicity than wild-type (wt) MTHFR genotype
tumours. Such a possible impact of MTHFR genotype may also
affect normal host tissues. So far, the influence of C677T and
A1298C polymorphisms on fluoropyrimidine sensitivity and/or
toxicity remains unknown.
Numerous experimental and clinical studies have previously
shown that elevated tumoral TS activity or expression is related to
FU resistance (Beck et al, 1994; Peters et al, 2002). The TS gene is
located on chromosome 18p. A genetic polymorphism has been
reported in the 50 regulatory region (cis-acting enhancer element)
of the TS promoter that presents either double or triple tandem
repeats of a 28bp sequence in Caucasian and Asian populations
(Horie et al, 1995; Marsh et al, 1999). In an expression assay, Horie
et al (1995) first reported that expression of the gene with triple
repeat was higher than that of the gene with double repeat. Clinical
studies have reported that triple repeat homozygous tumors (3R/
3R) exhibit either higher TS mRNA or TS protein levels as
compared to double repeat homozygous (2R/2R) (Kawakami et al,
2001b; Pullarkat et al, 2001). Recent clinical studies performed on
small sets of patients have suggested that 50 TS polymorphism
may influence fluoropyrimidine sensitivity, with lower response
rate in homozygous 3R/3R patients as compared to others
(Marsh et al, 2001; Pullarkat et al, 2001; Villafranca et al, 2001;
Park et al, 2002). We recently analysed 50 TS genotype on a large
set of metastatic colorectal cancer patients receiving FU-based
therapy and found similar response rates in 3R/3R, 3R/2R and 2R/
2R patients (Etienne et al, 2002). A second TS polymorphism
TS
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Figure 1 Folate metabolic pathways related to MTHFR and TS. 5-10
CH¼FH4, 5-10 methenyltetrahydrofolate; 5-10 CH2FH4, 5-10 methyle-
netetrahydrofolate; 5-CH3FH4, 5-methyltetrahydrofolate; 5-CHOFH4 (FA),
5-formyltetrahydrofolate; DHFR, dihydrofolate reductase; dTMP, deox-
ythymidine 50-monophosphate; dUMP, deoxyuridine 50-monophosphate;
FdUMP, 5-fluorodeoxyuridine 50-monophosphate; FdUrd, 5-fluorodeox-
yuridine; FH2, dihydrofolate; FH4, tetrahydrofolate; FU, 5-fluorouracil; MS,
methionine synthase; MTHFR, 5-10 methylenetetrahydrofolate reductase;
TK, thymidine kinase; TP, thymidine phosphorylase; TS, thymidylate
synthase.
Table 1 Cell line characteristics and FU sensitivity (mean7s.e. from three separate experiments)
Cell lines
Tumour type Name Origin FU IC50 (lM) Opt FU IC50 (lM) Basal CH2FH4 (pmolmg
 1 protein
 1)
MCF7 Pr Rochefort 6.372.0 1.370.3 0.970.3
T47D Pr Rochefort 10.271.1 1.870.2 ND
CAL51 CAL 4.170.1 4.170.1 ND
Breast ZR75 Pr Rochefort 1.070.3 0.270.4 0.570.1
CAL85-2 CAL 2.070.1 0.670.1 ND
8
> > > > > > <
> > > > > > :
CAL120 CAL 7.071.3 2.170.2 ND
CAL14 CAL 2.970.6 1.570.2 ND
WIDR EORTC 3.670.2 0.970.1 0.470
COLO205 ATCC (CCL222) 0.870.1 0.270.1 3.372.1
Colon SW620 ATCC (CCL227) 13.872.7 7.370.3 0.470.1
SW403 ATCC (CCL230) 0.670.1 0.270.3 ND
8
> > > > > > <
> > > > > > :
CAL124 CAL 0.370.1 0.170.4 ND
Intestine HUTU80 ATCC (HTB40) 9.770.9 9.770.1 ND
Pancreas HS766T ATCC (HTB134) 16.572.4 8.370.3 ND
CAL33 CAL 0.670.1 0.270.2 ND
CAL27 CAL 1.870.2 0.470.3 0.870.3
Head and neck Hep2 ATCC (CCL23) 25.473.5 8.670.1 ND
KB ATCC (CCL17) 7.371.1 1.670.2 1.370.1
8
> > > > <
> > > > :
Detroit 562 ATCC (CCL138) 2.971.0 1.070.3 0.370
Opt FU IC50¼optimal FU IC50 obtained with FA supplementation (see Material and Methods); ND¼not detectable; CH2FH4¼methylenetetrahydrofolate. Cell line origins:
CAL cell lines come from our institute; Pr Rochefort is from INSERM U 184, Montpellier, France; EORTC, European Organisation for Research and Treatment of Cancer; ATCC,
American Type Culture Collection (Rockeville, MD, USA).
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sconsisting of a 6bp deletion at bp 1494 in the 30 untranslated
region has recently been reported (Ulrich et al, 2000). The deleted
30 variant is associated with decreased TS mRNA levels in
colorectal tumours (Ulrich et al, 2000). No study has been
reported on the relationship between 30 TS polymorphism and
fluoropyrimidine sensitivity.
The purpose of the present study was to analyse the relation-
ship between major TS and MTHFR polymorphisms on FU
sensitivity. To this end, we investigated a large panel of 19 human
cancer cell lines representative of fluoropyrimidine-treated
tumours (digestive, breast, head and neck), and expressing
spontaneous sensitivity to FU. Special attention was paid to the
reduced folate status, and FU sensitivity was evaluated in the
absence or presence of FA supplementation in order to take into
account the different fluoropyrimidine-based protocols adminis-
tered to patients. In addition to the possible relationships between
studied polymorphisms and FU cytotoxicity, we analysed the
relationship between TS activity and polymorphisms, as well
as links between CH2FH4 basal concentrations and MTHFR
polymorphisms.
MATERIAL AND METHODS
Primers and probes
Primers and probes were all synthesised by Proligos (Paris,
France). For TS polymorphisms, forward and reverse primers were
GTGGCTCCTGCGTTTCCCCC and GCTCCGAGCCGGCCACAGG-
CA, respectively, for 50 TS polymorphism, and GACGAATGCA-
GAACACTTCT and AATCTGAGGGAGCTGAGTAAC, respectively,
for 30 TS polymorphism.
For MTHFR polymorphisms, anchor probes were labelled on the
30 extremity with fluorescein. Mutated specific probes were labelled
at the 50 extremity with LC-Red-640 for C677T and LC-Red-705 for
A1298C variants and were phosphorylated on their 30 extremity to
avoid extension by PCR.
Primers for C677T variants were: forward 50-TGG CAG GTT
ACC CCA AAG G-30; reverse 50-TGA TGC CCA TGT CGG TGC-30.
Labelled probes for C677T variants were: anchor 50-TGA GGC TGA
CCT GAA GCA CTT GAA GGA GAA GGT GTC T-fluo; C variant
(wild type) 50-Red 640-CGG GAG CCG ATT TCA TCA T-30 phos; T
variant (mutated) 50-Red 640-CGG GAG TCG ATT TCA TCA T-30
phos. Primers for A1298C variants were: forward 50-CTT TGG GGA
GCT GAA GGA CTA CTA C-30; reverse 50-CAC TTT GTG ACC ATT
CCG GTT TG-30. Labelled probes for A1298C variants were: anchor
50-AAG GAG GAG CTG CTG AAG ATG TGG GGG GAG GAG CT-
fluo; A variant (wild type) 50-Red 705-ACC AGT GAA GAA AGT
GTC TTT GA-30 phos; C variant (mutated) 50-Red 705-ACC AGT
GCA GAA AGT GTC TTT GA-30 phos.
Cell lines
This study was conducted on a panel of 19 human cancer cell lines
(six breast, seven digestive tract, five head and neck, one pancreas)
expressing spontaneous sensitivity to FU (not previously exposed
to FU), with IC50 ranging from 0.3 to 25mM (Table 1). Cell doubling
time ranged from 1.3 to 6.3 days (mean 2.7, median 2.2).
Biochemical investigations
Of the 19 cell line panel, 14 had been previously investigated for FU
sensitivity with or without FA supplementation, intracellular
reduced folate content, and TS activity (Che ´radame et al, 1997a),
as briefly described below. In order to match the physiological
circulating folate concentration in humans, cells were grown in a
folate-controlled medium for 10 days before experiments were
started (folate-free DMEM medium supplemented with 40nM of dl-
5-methyltetrahydrofolate, 0.1mM of l- ascorbic acid for folate
stabilisation, 10% FBS, 2mM glutamine, 50000Ul
 1 penicillin and
80mM streptomycin) and all experiments have been subsequently
performed in this folate-controlled medium.
Cytotoxicity experiments Cells were exposed for 5 days to various
FU (14 concentrations ranging from 0.01 to 500mM), FA (6
concentrations ranging from 0.01 to 300mM of pure l-FA) or
FUþFA concentrations (sextuplicates in 96-well microtitration
plates). Growth inhibition was assessed by the MTT test
(Carmichael et al, 1987) and the dose–effect curves were analysed
on GraphPad software (ISI, USA).
Intracellular reduced folate measurement After 5days of growth
(175cm
2 plates), cells were harvested, washed three times in
phosphate buffer saline at þ41C and cell pellets containing
approximately 50 10
6 cells were stored in liquid nitrogen. 5-10
Methylenetetrahydrofolate was measured on a 15000g cytosol, as
previously described (Che ´radame et al, 1997a), based on the
entrapment assay initially developed by Bunni et al (1988). This
assay is based on the stoicheiometric formation of a stable ternary
complex between CH2FH4, excess purified TS (0.225mM final
concentration), and excess
3H-FdUMP (0.35mM final concentra-
tion). Recovery calculated from controls containing known
CH2FH4 concentrations was 90% on average. Sensitivity limit
was 0.3pmolmg
 1 protein. Intra- and interassay reproducibility
were 9.4 and 25.0%, respectively.
Measurement of TS activity Thymidylate synthase activity was
measured according to the tritium-release assay initially described
by Spears and Gustavsson (1988) and modified by us (Etienne et al,
2002). Cells (4 10
6 cellsml
 1 in 50mM Tris HCl buffer pH 7.3
containing 2mM dithiothreitol) were sonicated on ice bed (three
times at 10s intervals) and centrifuged at 100000g for 30min
(þ41C). The assay consisted in incubating 25ml of cytosol with
excess
3H-dUMP (1mM final concentration) and CH2FH4 (0.62mM
final concentration) in a total volume of 55ml (in the previous
buffer). After 0, 10, 20 and 30min of incubation at þ371C, the
reaction was stopped on ice bed. The excess of
3H-dUMP was
removed by adding 300ml of activated charcoal (15%) containing
4% trichloracetic acid (5min centrifugation at 14000g, room
temperature). The
3H2O formed during the incubation was then
measured in an aliquot of the above supernatant. Results were
expressed as fmoles of
3H2O formed per min per mg of protein,
based on the linear regression obtained from the incubation times.
Cytosolic proteins were determined by the Bradford colorimetric
assay (Protein Assay Reagent, Biorad Laboratories, Germany) with
human serum albumin as standard. The sensitivity limit was
10fmolmin
 1mg
 1 protein. The CV for interassay reproducibility
(N¼7) was 15%.
Gene polymorphisms
Thymidylate synthase and MTHFR genetic polymorphisms were
analysed on DNA extracted from cell pellets stored in liquid
nitrogen.
Determination of 50 and 30 TS polymorphisms For the 50
polymorphism, a fragment containing the 28-bp repeats was
amplified (expected fragment size was 220bp for 2R and 248bp for
3R). For the 30 polymorphism, a fragment containing the 6bp
deletion was amplified (expected fragment sizes were 110bp for
the wild type and 104bp for the variant allele). In each case, PCR
were run on a GeneAmp
R PCR system 9700 (Applied Biosystems,
Courtabœuf, France) in a 25ml final volume containing 50ng of
genomic DNA, 1mM MgCl2, 2.5ml of buffer 10 , 1.25mM of
dNTPs, 0.15mM of each specific forward and reverse primer and
0.05Uml
 1 of Taq polymerase Cetus (Perkin Elmer, Courtaboeuf,
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sFrance). After 30 cycles of amplification (denaturation at 941C for
30s, annealing at 621C for 60s, and extension at 721C for 90s),
amplification products were electrophoresed on acrylamide gel at
8%. For 50 polymorphism, products of 220bp (2R/2R), 248bp (3R/
3R) or both (2R/3R) were observed. For 30 polymorphism,
products of 110bp (6bp/6bp), 104bp (0bp/0bp) or both (6bp/
0bp) were observed.
Determination of MTHFR polymorphisms The C677T (Ala-Val)
and A1298C (Glu-Ala) variants were analysed simultaneously by
means of melting curve analyses on LightCycler (Roche), based on
the fluorescence resonance energy transfer (FRET) principle (see
Figure 2 for a typical example of analysis). We used a method
derived from that initially described by Nakamura et al (2002). A
duplex PCR amplification was first run in 20ml final volume
containing 80ng genomic DNA (2ml), 2ml of ready-to-use Hotstart
PCR mixture (LightCycler Faststart DNA Master Hybridization
Probes kit, Roche Diagnostic, France), 3mM MgCl2, 0.2mM of each
primer, 0.2mM of each specific anchor fluorescein-labelled probe,
and 0.4mM of each specific wt variant (C 677 or A 1298 LC-red-
labelled probe), in PCR grade water. After DNA denaturation and
enzyme activation (8min at 951C), DNA was amplified for 45
cycles (15s at 951C, 10s at 551C and 10s at 721C). At the end of
PCR, melting curves of the DNA/probes complexes synthesised
were performed by increasing temperature gradually (0.11Cs
 1)
up to 951C. Methylenetetrahydrofolate reductase variant
identification was based on the fact that the melting temperature
of the DNA/probe complex is lower in the case of DNA/probe T/C
mismatch at nucleotide 677 or DNA/probe C/A mismatch at
nucleotide 1298. The C677T genotype was monitored at 640nm
and the melting curve showed a single peak at 641C for C/C
samples, a single peak at 551C for T/T samples, and two peaks
for heterozygous cell lines. The A1298C genotype was monitored
at 705nm and the melting curve showed a single peak at 631C for
A/A samples, a single peak at 601C for C/C samples, and two
peaks for heterozygous cell lines. In the event of DNA/probe
mismatch, a second PCR (duplex PCR if necessary) was
conducted with specific mutated (mut) variants (T 677 or C 1298
LC-red-labelled probes), in order to confirm the presence of the
specific analysed mutation.
Data analysis and statistics
All experiments were performed in triplicate. 5-Fluorouracil IC50
was defined as the concentration causing 50% growth inhibition as
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Figure 2 Typical example of melting curves and melting peaks used to
genotype C677T MTHFR gene mutation. A wt probe is used. Melting peak
temperatures obtained from a derivative of the melting curves are 641C for
homozygous wt (CC), 641C and 551C for heterozygous (CT) and 551C for
homozygous mut types (TT).
Table 2 Description of TS activity, TS and MTHF polymorphisms
Cell lines TS polymorphisms MTHFR polymorphisms
Tumour type Name TS activity* (pmolmin
 1mg
 1 protein) 50 genotype 30 genotype C677T genotype A1298C genotype
MCF7 18.173.0 3R/3R 6bp/6bp T/T A/A
T47D 29.171.0 2R/2R 6bp/6bp T/T A/A
CAL51 48.675.6 2R/3R 6bp/6bp C/T A/C
Breast ZR75 14.470.9 2R/3R 6bp/6bp C/T A/C
CAL85-2 41.670.9 2R/3R 6bp/0bp C/C A/A
8
> > > > > > <
> > > > > > :
CAL120 17.171.5 3R/3R 6bp/0bp C/C A/A
CAL14 11.672.1 2R/2R 6bp/6bp C/T A/C
WIDR 9.573.0 2R/2R 6bp/6bp C/T A/C
COLO205 19.973.8 2R/2R 6bp/6bp C/T A/A
Colon SW620 24.672.4 2R/2R 6bp/6bp T/T A/A
SW403 6.770.2 3R/3R 0bp/0bp C/T A/A
8
> > > > > > <
> > > > > > :
CAL124 7.2 2R/2R 6bp/6bp C/C C/C
Intestine HUTU80 82.8710.0 2R/2R 6bp/0bp C/T A/A
Pancreas HS766T 17.270.3 3R/3R 6bp/6bp C/C A/A
CAL33 34.370.9 2R/3R 6bp/6bp C/C A/C
CAL27 38.475.8 2R/3R 6bp/0bp C/C C/C
Head and neck Hep2 58.373.9 2R/3R 0bp/0bp C/T A/A
KB 9.771.9 3R/3R 0bp/0bp C/T A/C
8
> > > > <
> > > > :
Detroit 562 18.6 3R/3R 0bp/0bp C/T A/C
TS¼thymidylate synthase; MTHFR¼methylenetetrahydrofolate reductase.
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scompared to control cells. In the conditions with FA supplementa-
tion, for each tested FA concentration we computed a potentiation
factor (F) equal to the FU IC50 without FA divided by the FU IC50
with FA. Optimal FU IC50 corresponded to the IC50 obtained in the
presence of optimal FA, that is, allowing 90% of the maximal F
value to be reached. Correlations between TS activity and FU IC50s
were tested by means of Pearson correlation, after logarithm
transformation that allows the Gaussian distribution to be fitted.
All other statistics were performed by means of nonparametric
tests: Spearman rank correlation, Kruskal–Wallis test, Mann–
Whitney test. For this latter test, mut vs wt comparison was
performed by merging homozygous and heterozygous mutated
variants vs homozygous wt cell lines. Statistics were performed on
SPSS software (Chicago, USA).
RESULTS
Cell line sensitivity to FU7FA, intracellular reduced
folates and TS activity
Table 1 summarises cell line sensitivity to FU alone or in
combination with optimal FA concentration. In two cell lines
(CAL51 and HUTU 80), FU cytotoxicity was not enhanced by FA.
The basal intracellular CH2FH4 concentration was detectable in
nine cell lines out of the 19 investigated. Thymidylate synthase
activity (Table 2) ranged between 6.7 and 82.8pmolmin
 1mg
 1
protein (mean 27). The greater the FU sensitivity, the lower the TS
activity (P¼0.078 and 0.032, in the absence and presence of
optimal FA concentration, respectively). Basal CH2FH4 was not
linked to FU sensitivity.
50 and 30 TS polymorphisms
Distribution of 50 TS genotype (Table 2) was 36.8% 2R/2R (n¼7),
31.6% 2R/3R (n¼6) and 31.6% 3R/3R (n¼6). Distribution of 30
TS genotype (Table 2) was 57.9% 6bp/6bp (n¼11), 21.1% 6bp/
0bp (n¼4) and 21.1% 0bp/0bp (n¼4). Cell doubling time was
not linked to 50 or 30 TS genotypes.
Thymidylate synthase activity was significantly different
according to 50 TS genotype, heterozygous cell lines exhibiting
significantly higher TS activities than homozygous ones
(median 20, 40 and 17pmolmn
 1mg
 1 in 2R/2R, 2R/3R and 3R/
3R, respectively; Kruskal–Wallis P¼0.050, Figure 3A). No
significant relationship was observed between TS activity
and 30 TS genotype (Kruskal–Wallis P¼0.23, Figure 3B). Whether
in the absence or presence of FA, FU sensitivity was not
statistically associated with either 50 or 30 TS polymorphism
(Figure 4).
C677T and A1298C MTHFR polymorphisms
Distribution of C677T genotype was 31.6% C/C (n¼6), 52.6% C/T
(n¼10), 15.8% T/T (n¼3) and that of A1298C was 52.6% A/A
(n¼10), 36.8% A/C (n¼7) and 10.5% C/C (n¼2) (Table 2).
From Tables 1 and 2, it appears that basal CH2FH4 concentra-
tions were not detectable in 5/6 homozygous wt (C/C) 677
genotype, whereas detectable concentrations were observed in
7/13 mut (T/T and C/T) 677 genotype. Also, basal CH2FH4
concentrations were below detection limit in 7/10 homozygous
wt (A/A) 1298 genotype, in contrast with detectable concentra-
tions observed in 5/9 mut (C/C and A/C) 1298 genotype. The
above observations, which did not reach statistical significance,
are depicted in Figure 5. Of note, in the three cell lines
with homozygous wt genotype for both 677 and 1298
(CAL85-2, CAL120, HS766T), CH2FH4 was always below the
detection limit.
Whether in the absence or presence of FA, FU sensitivity (FU
IC50 or optimal (Opt) FU IC50) was not linked to C677T genotype
(C/C vs C/T vs T/T: nonsignificant, Figure 6; wt (C/C) vs mut
(C/TþT/T): nonsignificant). In contrast, FU efficacy tended
to be higher in mutated A1298C variants (C/CþA/C), both in
‘physiological-folate’ conditions (Figure 7A) and in the presence
of optimal FA concentration (Figure 7B). In ‘physiological-
folate’ conditions, FU IC50 ranged from 0.6 to 25.4mM (median
8.4) in the 10 cell lines exhibiting wt A/A 1298 variant, whereas
IC50 were comprised between 0.3 and 7.3 (median 2.9) in the
nine cell lines exhibiting mutated A/C or C/C 1298 variants;
this difference was very close to statistical significance
(Mann–Whitney, P¼0.055). A similar pattern of distribution,
although less significant (Mann–Whitney, P¼0.085), was
observed for Opt FU IC50, that is in the presence of optimal
FA concentrations.
DISCUSSION
In the context of cancer treatment, pharmacogenetic exploration
may result, in the future, in the replacement of tedious and heavy
phenotypic explorations either at blood level (pharmacokinetics)
or at tumour level (prognostic/predictive markers) by genetic
analyses performed on easily obtainable DNA samples from
6 6 7 N =
5' TS polymorphism
3R/3R 2R/3R 2R/2R
T
S
 
a
c
t
i
v
i
t
y
 
(
p
m
o
l
 
m
i
n
−
1
 
m
g
−
1
) 100
80
60
40
20
0
A
4 4 11 N =
3' TS polymorphism
6 bp/0 bp
T
S
 
a
c
t
i
v
i
t
y
 
(
p
m
o
l
 
m
i
n
−
1
 
m
g
−
1
)
100
80
60
40
20
0
B
0 bp/0 bp 6 bp/6 bp
Figure 3 Distribution of TS enzymatic activity according to 50 TS
polymorphism (A)o r3 0 TS polymorphism (B). Boxes delimit the first and
third quartiles, with the median inside, and bars represent the range of
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The observation that pharmacogenetic status faithfully reflects
phenotypic changes at the target level is a prerequisite of clinical
pharmacogenetic applications. In fact, from a theoretical point
of view, genetic polymorphisms are identical in all tissues.
However, the possibility of a clonal selection emerging from a
heterozygous subject during the process of carcinogenesis cannot
be ruled out. This strengthens the need to examine the impact of
cancer-treatment-related gene polymorphisms at the tumoral
target itself.
The aim of the present study was thus to analyse the impact
at tumoral target level of polymorphisms of two major genes
related to DNA synthesis, namely TS and MTHFR polymorphisms,
which may influence FU cytotoxicity. To our knowledge, the
present experimental study is the first one designed for this
purpose. Moreover, the present model was specially controlled for
reduced folate status (folate-free medium supplemented with
physiological-compatible CH2FH4 concentrations) and experi-
ments were conducted both in the absence and presence of
optimal FA concentrations, in order to mimic the two opposite
situations regarding FA supplementation in FU-based treated
patients. To this end, we closely explored a panel of 19 cancer cell
lines expressing spontaneous FU sensitivity and covering the
major fluoropyrimidine-treated localisations (digestive tract,
breast, head and neck). The 50 TS and C677T MTHFR genotype
frequencies were in the range of those reported in Caucasian
populations (Marsh et al, 1999; Ueland et al, 2001), strengthening
the relevance of the present model. The 30TS and A1298C MTHFR
polymorphisms have been less extensively studied in Caucasian
populations, thus frequency comparisons with published data were
difficult to perform. The chosen experimental approach did not
allow allelotype analyses to be performed, since such analyses
require large population studies.
Up to now, clinical studies investigating the influence of 50 TS
gene polymorphism on TS mRNA or protein level have given
rather contrasting results. A retrospective study conducted on
52 colorectal tumour specimens reported that triple repeat
homozygous (3R/3R) exhibit 3.6-fold higher TS mRNA levels as
compared to double repeat homozygous (2R/2R) (Pullarkat et al,
2001). Another study conducted on 133 cancer biopsies (mostly
colorectal cancer) showed no difference in TS mRNA level
according to 50 TS genotype, but demonstrated higher TS protein
concentration in 3R/3R as compared to 2R/2R (Kawakami et al,
2001b). One of the major findings of the present study is that
TS enzymatic activity is significantly influenced by the 50TS
genotype. This result is somewhat surprising since TS activity was
significantly higher in 2R/3R heterozygous cell lines (Table 2,
Figure 3A). However, superimposable conclusions were drawn
from the only available data on the link between TS activity and
TS polymorphism, which we recently published on colorectal
cancer patients (Etienne et al, 2002). Mandola et al (2003)
recently described an additional G-C SNP within the second
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srepeat of the triple tandem that may influence the trans-
criptional activity of the gene. Such an additional polymorphism
in the 50 regulatory region with functional consequences on
transcriptional activity may complicate the links between TS
activity and tandem repeat polymorphisms. This could explain
the present unexpected data with a high TS activity in 2R/3R
cell lines. In contrast to 50 TS genotype, the present experimental
data do not support a significant influence of 30 TS genotype on
TS enzymatic activity.
Importantly, the present experimental model was powerful
enough to demonstrate the well-established relationship between
FU sensitivity and low TS expression (Beck et al, 1994; Peters et al,
2002), herein evaluated as enzymatic activity. In contrast, whether
in the absence or presence of FA, FU sensitivity was not
statistically associated with either 50 or 30 TS polymorphism
(Figure 4). The absence of impact of 50 TS genotype on FU
sensibility closely agrees with our previous prospective clinical
study (Etienne et al, 2002), reporting identical response rates
between 2R/2R, 2R/3R and 3R/3R patients (genotype analysed on
liver metastasis) in 88 patients receiving FU–FA chemotherapy.
However, the present results are not in line with other recent
clinical studies, most of which were conducted on rather small sets
of colorectal cancer patients. Higher response rates were thus
reported in 2R/2R patients by Pullarkat et al (2001) in 50 patients
receiving protracted FU infusion and by Park et al (2002) in 24
capecitabine-treated patients. Also, lower downstaging was de-
monstrated in 3R/3R tumours by Villafranca et al (2001) on 66
rectal cancer patients receiving FU-based chemoradiotherapy
protocols. A significant shorter survival rate in 3R/3R patients
receiving FU-based adjuvant chemotherapy was demonstrated by
Iacopetta et al (2001). The value of 50 TS genotype for predicting
fluoropyrimidine responsiveness and its use as a surrogate of TS
measurement at the target level is still far from being clearly
established, and requires additional large-scale prospective
clinical studies including the recently reported G-C SNP
within the triple tandem repeat (Kawakami and Watanabe, 2003;
Mandola et al., 2003).
Methylenetetrahydrofolate reductase is a key enzyme of the
folate metabolic pathway (Figure 1). Two SNPs (C677T and
A1298C) associated with altered phenotypes have been described
for this enzyme (Frosst et al, 1995; Weisberg et al, 1998).
The mutated forms of these variants (i.e. 677TT and 1298CC)
exhibit significantly lower enzymatic activity, and should theore-
tically lead to an accumulation of intracellular CH2FH4 concentra-
tions as compared to wt forms. Consequently, C677T and A1298C
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sMTHFR polymorphisms may influence the pharmacodynamics of
fluoropyrimidines since they control the intracellular concentra-
tion of the specific reduced folate required for optimal TS
inhibition. This hypothesis is supported by preclinical and clinical
data (Danenberg and Danenberg, 1978; Houghton et al, 1981;
Rustum et al, 1987; Keyomarsi and Moran, 1988; Che ´radame et al,
1997a,b) demonstrating the impact of CH2FH4 intratumoral
concentrations on FU cytotoxicity. Recent clinical studies have
suggested that MTHFR polymorphisms may be associated with
methotrexate pharmacodynamics (Ulrich et al, 2001; Urano et al,
2002). However, no study has so far reported their impact on
fluoropyrimidine sensitivity (Wisotzkey et al, 1999). First of all, the
present data closely concord with the theoretical impact of C677T
and A1298C polymorphisms on CH2FH4 intracellular pool: five out
of six homozygous wt C677 variants and seven out of 10
homozygous wt A1298 variants exhibited nondetectable CH2FH4
concentrations, in contrast to six out of 13 T/T or C/T 677 variants,
and four out of nine C/C or A/C 1298 variants (Figure 5, Tables 1
and 2). These data agree with those of Kawakami et al (2001a) who
recently reported relationships between MTHFR genotypes and
tumoral-reduced folates in gastrointestinal cancer .
The C677T genotype did not significantly influence FU
cytotoxicity, whether in the absence or presence of optimal FA
supplementation (Figure 6). However, FU sensitivity was related to
A1298C MTHFR genotype: homozygous mutated cell lines (C/C)
were the more sensitive, homozygous wt (A/A) were the more
resistant, heterozygous cell lines (A/C) exhibiting intermediary
sensitivity (Figure 7, Tables 1 and 2). The influence of A1298C
MTHFR polymorphism on FU sensitivity was observed irrespec-
tive of the absence or presence of optimal FA supplementation.
These stimulating results show a trend close to statistical
significance (P¼0.055 and 0.085 in the absence and presence of
FA, respectively) and are thus consistent with the initial hypothesis
that MTHFR genotypes associated with altered enzymatic activity
may be more FU sensitive.
Altogether, it is hoped that the present data will encourage
future studies to consider not only TS polymorphisms but also
MTHFR polymorphisms as potential predictors of fluoropyrimi-
dine responsiveness and/or toxicity. Both tumoral and constitu-
tional genotype analyses should be taken into account in clinical
prospective studies, particularly regarding the design of future FU-
based chemotherapy study.
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